Connection
Thomas Kartika to Protein Kinase Inhibitors
This is a "connection" page, showing publications Thomas Kartika has written about Protein Kinase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.749 |
|
|
|
-
Kartika T, Buitrago L, Li J, Cunningham-Rundles C, Coller BS. Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fc? receptor (Fc?R) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy. Res Pract Thromb Haemost. 2026 Jul; 10(5):106841.
Score: 0.607
-
West MT, Kartika T, Paquin AR, Liederbauer E, Zheng TJ, Lane L, Thein K, Shatzel JJ. Thrombotic events in patients using cyclin dependent kinase 4/6 inhibitors, analysis of existing ambulatory risk assessment models and the potential influences of tumor specific risk factors. Curr Probl Cancer. 2022 04; 46(2):100832.
Score: 0.111
-
West MT, Goodyear SM, Hobbs EA, Kaempf A, Kartika T, Ribkoff J, Chun B, Mitri ZI. Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer. Oncologist. 2023 08 03; 28(8):682-690.
Score: 0.031